Dr. Reddy's Laboratories trades higher on the bourses

Dr. Reddy’s Laboratories is currently trading at Rs. 2888.00, up by 27.65 points or 0.97% from its previous closing of Rs. 2860.35 on the BSE.

The scrip opened at Rs. 2877.00 and has touched a high and low of Rs. 2929.00 and Rs. 2877.00 respectively. So far 20,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 2974.00 and Rs. 2814.80 respectively. The current market cap of the company is Rs. 49,271.00 crore.

The promoters holding in the company stood at 31.21%, while Institutions and Non-Institutions held 53.10% and 15.68% respectively.

Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, US, has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05% from the US Food and Drug Administration (USFDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planned for the coming quarter.

Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.